vs
Apellis Pharmaceuticals, Inc.（APLS）与HANCOCK WHITNEY CORP（HWC）财务数据对比。点击上方公司名可切换其他公司
HANCOCK WHITNEY CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$295.0M vs $199.9M），HANCOCK WHITNEY CORP净利率更高（16.1% vs -29.5%，领先45.6%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -19.7%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -9.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
汉考克惠特尼公司是总部位于美国密西西比州格尔夫波特的银行控股企业，在密西西比、阿拉巴马、佛罗里达、路易斯安那、得克萨斯五州共运营237家网点。它是新奥尔良圣徒队、路易斯安那州立大学体育队、路易斯安那大学拉法叶分校运动队的官方合作银行，独家发行对应队伍的官方借记卡，还独家提供LSU老虎队专属信用卡。
APLS vs HWC — 直观对比
营收规模更大
HWC
是对方的1.5倍
$199.9M
营收增速更快
APLS
高出13.8%
-19.7%
净利率更高
HWC
高出45.6%
-29.5%
两年增速更快
APLS
近两年复合增速
-9.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $295.0M |
| 净利润 | $-59.0M | $47.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 16.1% |
| 营收同比 | -5.9% | -19.7% |
| 净利润同比 | -62.2% | -60.3% |
| 每股收益（稀释后） | $-0.40 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHWC
| Q1 26 | — | $295.0M | ||
| Q4 25 | $199.9M | $389.3M | ||
| Q3 25 | $458.6M | $385.7M | ||
| Q2 25 | $178.5M | $375.5M | ||
| Q1 25 | $166.8M | $364.7M | ||
| Q4 24 | $212.5M | $364.8M | ||
| Q3 24 | $196.8M | $367.7M | ||
| Q2 24 | $199.7M | $359.6M |
净利润APLSHWC
| Q1 26 | — | $47.4M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $127.5M | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $115.6M | ||
| Q2 24 | $-37.7M | — |
营业利润率APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 40.7% | ||
| Q3 25 | 48.7% | 41.6% | ||
| Q2 25 | -18.6% | 38.5% | ||
| Q1 25 | -50.0% | 40.9% | ||
| Q4 24 | -12.3% | 41.3% | ||
| Q3 24 | -24.0% | 39.5% | ||
| Q2 24 | -14.7% | 40.3% |
净利率APLSHWC
| Q1 26 | — | 16.1% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 33.0% | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 31.4% | ||
| Q2 24 | -18.9% | — |
每股收益（稀释后）APLSHWC
| Q1 26 | — | $0.57 | ||
| Q4 25 | $-0.40 | $1.48 | ||
| Q3 25 | $1.67 | $1.49 | ||
| Q2 25 | $-0.33 | $1.32 | ||
| Q1 25 | $-0.74 | $1.38 | ||
| Q4 24 | $-0.30 | $1.40 | ||
| Q3 24 | $-0.46 | $1.33 | ||
| Q2 24 | $-0.30 | $1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $223.7M |
| 总债务越低越好 | — | $1.6B |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $35.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSHWC
| Q1 26 | — | $223.7M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSHWC
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $199.4M | ||
| Q3 25 | — | $210.7M | ||
| Q2 25 | — | $210.6M | ||
| Q1 25 | — | $210.6M | ||
| Q4 24 | — | $210.5M | ||
| Q3 24 | — | $236.4M | ||
| Q2 24 | — | $236.4M |
股东权益APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $4.5B | ||
| Q3 25 | $401.2M | $4.5B | ||
| Q2 25 | $156.3M | $4.4B | ||
| Q1 25 | $164.2M | $4.3B | ||
| Q4 24 | $228.5M | $4.1B | ||
| Q3 24 | $237.1M | $4.2B | ||
| Q2 24 | $264.3M | $3.9B |
总资产APLSHWC
| Q1 26 | — | $35.5B | ||
| Q4 25 | $1.1B | $35.5B | ||
| Q3 25 | $1.1B | $35.8B | ||
| Q2 25 | $821.4M | $35.2B | ||
| Q1 25 | $807.3M | $34.8B | ||
| Q4 24 | $885.1M | $35.1B | ||
| Q3 24 | $901.9M | $35.2B | ||
| Q2 24 | $904.5M | $35.4B |
负债/权益比APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $541.8M | ||
| Q3 25 | $108.5M | $158.8M | ||
| Q2 25 | $4.4M | $125.8M | ||
| Q1 25 | $-53.4M | $104.2M | ||
| Q4 24 | $19.4M | $625.7M | ||
| Q3 24 | $34.1M | $162.5M | ||
| Q2 24 | $-8.3M | $105.0M |
自由现金流APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $523.1M | ||
| Q3 25 | $108.3M | $155.0M | ||
| Q2 25 | $4.4M | $122.0M | ||
| Q1 25 | $-53.4M | $100.2M | ||
| Q4 24 | $19.3M | $615.5M | ||
| Q3 24 | — | $158.6M | ||
| Q2 24 | $-8.4M | $103.7M |
自由现金流率APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 134.4% | ||
| Q3 25 | 23.6% | 40.2% | ||
| Q2 25 | 2.5% | 32.5% | ||
| Q1 25 | -32.0% | 27.5% | ||
| Q4 24 | 9.1% | 168.7% | ||
| Q3 24 | — | 43.1% | ||
| Q2 24 | -4.2% | 28.8% |
资本支出强度APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.8% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.0% | 2.8% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 0.4% |
现金转化率APLSHWC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.25× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HWC
暂无分部数据
